A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family

Journal of Immunology

Volumn 183, Issue 4, 2009, Pages 2565-2574

  Ricklin, Daniel ^a   Tzekou, Apostolia ^a   Garcia, Brandon L ^b   Hammel, Michal ^c   McWhorter, William J ^b   Sfyroera, Georgia ^a   Wu, You Qiang ^a   Holers, V Michael ^d   Herbert, Andrew P ^e   Barlow, Paul N ^e   Geisbrecht, Brian V ^b   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BACTERIAL PROTEIN; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; FIBRINOGEN; STAPHYLOCOCCAL COMPLEMENT INHIBITOR PROTEIN; UNCLASSIFIED DRUG; COMPLEMENT INHIBITOR;

ARTICLE; BACTERIAL VIRULENCE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COMPLEMENT SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN TARGETING; STAPHYLOCOCCUS AUREUS; CHEMISTRY; HUMAN; IMMUNOLOGY; METABOLISM; MULTIGENE FAMILY; PATHOGENICITY; PHYSIOLOGY; VIRULENCE;

COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY; COMPLEMENT C3B; COMPLEMENT FACTOR B; COMPLEMENT FACTOR H; COMPLEMENT INACTIVATOR PROTEINS; HUMANS; MULTIGENE FAMILY; PROTEIN BINDING; STAPHYLOCOCCUS AUREUS; VIRULENCE;

EID: 70149084212     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901443     Document Type: Article

References (46)

1. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
2. Lee, L. Y., M. Hook, D. Haviland, R. A. Wetsel, E. O. Yonter, P. Syribeys, J. Vernachio, and E. L. Brown. 2004. Inhibition of complement activation by a secreted Staphylococcus aureus protein. J. Infect. Dis. 190: 571-579.
3. Lee, L. Y., Y. J. Miyamoto, B. W. McIntyre, M. Hook, K. W. McCrea, D. McDevitt, and E. L. Brown. 2002. The Staphylococcus aureus map protein is an immunomodulator that interferes with T cell-mediated responses. J. Clin. Invest. 110: 1461-1471.
4. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6: 132-142.
5. Chavakis, T., K. T. Preissner, and M. Herrmann. 2007. The anti-inflammatory activities of Staphylococcus aureus. Trends Immunol. 28: 408-418.
6. Foster, T. J. 2005. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3: 948-958.
7. Ricklin, D., S. K. Ricklin-Lichtsteiner, M. M. Markiewski, B. V. Geisbrecht, and J. D. Lambris. 2008. Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. J. Immunol. 181: 7463-7467.
8. Rooijakkers, S. H., M. Ruyken, A. Roos, M. R. Daha, J. S. Presanis, R. B. Sim, W. J. van Wamel, K. P. van Kessel, and J. A. van Strijp. 2005. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 6: 920-927.
9. Rooijakkers, S. H., F. J. Milder, B. W. Bardoel, M. Ruyken, J. A. van Strijp, and P. Gros. 2007. Staphylococcal complement inhibitor: structure and active sites. J. Immunol. 179: 2989-2998.
10. Hammel, M., G. Sfyroera, D. Ricklin, P. Magotti, J. D. Lambris, and B. V. Geisbrecht. 2007. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 8: 430-437.
11. Hammel, M., G. Sfyroera, S. Pyrpassopoulos, D. Ricklin, K. X. Ramyar, M. Pop, Z. Jin, J. D. Lambris, and B. V. Geisbrecht. 2007. Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. J. Biol. Chem. 282: 30051-30061.
12. Upadhyay, A., J. D. Burman, E. A. Clark, E. Leung, D. E. Isenman, J. M. van den Elsen, and S. Bagby. 2008. Structure-function analysis of the C3 binding region of Staphylococcus aureus immune subversion protein Sbi. J. Biol. Chem. 283: 22113-22120.
13. Jongerius, I., J. Kohl, M. K. Pandey, M. Ruyken, K. P. van Kessel, J. A. van Strijp, and S. H. Rooijakkers. 2007. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 204: 2461-2471.
14. Burman, J. D., E. Leung, K. L. Atkins, M. N. O'Seaghdha, L. Lango, P. Bernado, S. Bagby, D. I. Svergun, T. J. Foster, D. E. Isenman, and J. M. H. van den Elsen. 2008. Interaction of human complement with SBI, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus. J. Biol. Chem. 283: 17579-17593.
15. Ricklin, D., and J. D. Lambris. 2007. Complement-targeted therapeutics. Nat. Biotechnol. 25: 1265-1275.
16. Rooijakkers, S. H., J. Wu, M. Ruyken, R. van Domselaar, K. L. Planken, B. J. C. Janssen, D. Ricklin, A. Tzekou, J. D. Lambris, J. A. van Strijp, and P. Gros. 2009. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 10: 721-727.
17. Sarrias, M. R., S. Franchini, G. Canziani, E. Argyropoulos, W. T. Moore, A. Sahu, and J. D. Lambris. 2001. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220. J. Immunol. 167: 1490-1499.
18. Wu, J., Y.-Q. Wu, D. Ricklin, B. Janssen, J. D. Lambris, and P. Gros. 2009. Structure of complement fragment C3b - factor H and implications for host protection by complement regulators. Nat. Immunol. 10: 728-733.
19. Herbert, A. P., D. Uhrin, M. Lyon, M. K. Pangburn, and P. N. Barlow. 2006. Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure. J. Biol. Chem. 281: 16512-16520.
20. Asokan, R., J. Hua, K. A. Young, H. J. Gould, J. P. Hannan, D. M. Kraus, G. Szakonyi, G. J. Grundy, X. S. Chen, M. K. Crow, and V. M. Holers. 2006. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-α: a potential role in systemic lupus erythematosus. J. Immunol. 177: 383-394.
21. Geisbrecht, B. V., S. Bouyain, and M. Pop. 2006. An optimized system for expression and purification of secreted bacterial proteins. Protein Expr. Purif. 46: 23-32.
22. Myszka, D. G. 1999. Improving biosensor analysis. J. Mol. Recognit. 12: 279-284.
23. Putnam, C. D., M. Hammel, G. L. Hura, and J. A. Tainer. 2007. X-ray solution scattering (SAXS) combined with crystallography and computation: defining accurate macromolecular structures, conformations and assemblies in solution. Q. Rev. Biophys. 40: 191-285.
24. Guinier, A., and F. Fournet. In Small Angle Scattering of X-rays. Wiley Interscience: New York; 1955.
25. Svergun, D. 1992. Determination of the regularization parameter in indirecttransform methods using perceptual criteria. J. Appl. Cryst. 25: 495-503.
26. Mylonas, F., and D. I. Svergun. 2007. Accuracy of molecular mass determination of proteins in solution by small-angle X-ray scattering. J. Appl. Cryst. 40: s245-s249.
27. Svergun, D., C. Baraberato, and M. H. Koch. 1995. CRYSOL: a program to evaluate X-ray solution scattering of biological macromolecules from atomic coordinates. J. Appl. Cryst. 28: 768-773.
28. Konarev, P. V., V. V. Volkov, A. V. Sokolova, M. H. J. Koch, and D. I. Svergun. 2003. PRIMUS: a Windows PC-based system for small-angle scattering data analysis. J. Appl. Cryst. 36: 1277-1282.
29. Janssen, B. J., A. Christodoulidou, A. McCarthy, J. D. Lambris, and P. Gros. 2006. Structure of C3b reveals conformational changes that underlie complement activity. Nature 444: 213-216.
30. Alsenz, J., J. D. Lambris, T. F. Schulz, and M. P. Dierich. 1984. Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochem. J. 224: 389-398. (Pubitemid 15168431)
31. Haspel, N., D. Ricklin, B. V. Geisbrecht, L. E. Kavraki, and J. D. Lambris. 2008. Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d. Protein Sci. 17: 1894-1906.
32. Nishida, N., T. Walz, and T. A. Springer. 2006. Structural transitions of complement component C3 and its activation products. Proc. Natl. Acad. Sci. USA 103: 19737-19742.
33. Harris, C. L., R. J. Abbott, R. A. Smith, B. P. Morgan, and S. M. Lea. 2005. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J. Biol. Chem. 280: 2569-2578.
34. Nilsson, B., R. Larsson, J. Hong, G. Elgue, K. N. Ekdahl, A. Sahu, and J. D. Lambris. 1998. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 92: 1661-1667.
35. Harboe, M., G. Ulvund, L. Vien, M. Fung, and T. E. Mollnes. 2004. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138: 439-446.
36. Neuhaus, F. C., and J. Baddiley. 2003. A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in Gram-positive bacteria. Microbiol. Mol. Biol. Rev. 67: 686-723.
37. Löfås S., and B. Johnsson. 1990. A novel hydrogel matrix on gold surfaces in surface plasmon resonance sensors for fast and efficient covalent immobilization of ligands. J. Chem. Soc. Chem. Commun. 1526-1528.
38. Ricklin, D., and J. D. Lambris. 2007. Exploring the complement interaction network using surface plasmon resonance. Adv. Exp. Med. Biol. 598: 260-278.
39. Garcia, B. L., A. Tzekou, K. X. Ramyar, W. J. McWorther, D. Ricklin, J. D. Lambris, and B. V. Geisbrecht. 2009. Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). Acta Crystallogr. Sec. F Struct. Biol. Cryst. Commun. 65: 482-485.
40. Hack, C. E., J. Paardekooper, R. J. Smeenk, J. Abbink, A. J. Eerenberg, and J. H. Nuijens. 1988. Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3: an analysis with monoclonal antibodies. J. Immunol. 141: 1602-1609.
41. Becherer, J. D., J. Alsenz, I. Esparza, C. E. Hack, and J. D. Lambris. 1992. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. Biochemistry 31: 1787-1794.
42. Katschke, K. J., Jr., S. Stawicki, J. Yin, M. Steffek, H. Xi, L. Sturgeon, P. E. Hass, K. Loyet, L. Deforge, Y. Wu, et al. 2009. Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J. Biol. Chem. 284: 10473-10479.
43. Gordon, D. L., R. M. Kaufman, T. K. Blackmore, J. Kwong, and D. M. Lublin. 1995. Identification of complement regulatory domains in human factor H. J. Immunol. 155: 348-356.
44. Janssen, B. J., E. F. Halff, J. D. Lambris, and P. Gros. 2007. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 282: 29241-29247.
45. Weis, J. J., T. F. Tedder, and D. T. Fearon. 1984. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc. Natl. Acad. Sci. USA 81: 881-885. (Pubitemid 14197605)
46. DiScipio, R. G. 1981. The binding of human complement proteins C5, factor B, β1H and properdin to complement fragment C3b on zymosan. Biochem J. 199: 485-496.